Subscribe

Please type this word to confirm you're human:
Showing posts with label Other. Show all posts
Showing posts with label Other. Show all posts

A Comprehensive Review of Environmental and Nutritional Influences on Epigenetic Change

Srushti Kudalkar1, Snigdha Ranjan1*, Shagun Arya1, Mugdha Pradhan1

1 Thrivetribe Wellness Solutions Private Limited, Pune City, Maharashtra, India – 411045.

Corresponding Author

Snigdha Ranjan
Thrivetribe Wellness Solutions Private Limited,
Sr. No. 36/1/1, Office No. 601, 602, 603, 6th Floor,
VCC Vantage 9, Mumbai–Bangalore Highway,
Baner, Pune City, Maharashtra, India – 411045.
E-mail: snigdha@ithrivein.com

Running Title

Environmental and Nutritional Epigenetic Influences

Abstract

Epigenetic mechanisms act as a bridge between genetic potential and environmental influence. This review synthesizes current evidence on how nutritional factors and environmental exposures such as diet-derived bioactive, micronutrient status, heavy metals, air pollutants, and endocrine disruptors shape DNA methylation, histone modifications, and non-coding RNA activity across the lifespan. Special emphasis is placed on sensitive developmental windows where epigenetic plasticity is highest and long-term health trajectories are determined. We also outline links to metabolic disease, neurodevelopment, carcinogenesis, and intergenerational effects, while identifying major gaps and future directions in environmental and nutritional epigenomics. Collectively, this evidence positions the epigenome as a modifiable interface linking diet and environmental exposures to long-term health outcomes through epigenetic reprogramming, with important implications for preventive and personalized nutritional strategies.

Keywords

Epigenetic, Environmental exposures, Nutritional epigenomics, DNA methylation

References

  1. Saul D, Kosinsky RL. Epigenetics of Aging and Aging-Associated Diseases. Int J Mol Sci. 2021;22(1):401.
  2. Tiffon C. The Impact of Nutrition and Environmental Epigenetics on Human Health and Disease. Int J Mol Sci. 2018;19(11):3425.
  3. Paul B, Barnes S, Demark-Wahnefried W, et al. Clin Epigenetics. 2015;7(1):112.
  4. Bekdash RA. Epigenetics, Nutrition, and the Brain. Int J Mol Sci. 2024;25(7):4036.
  5. Ruiz-Hernandez A, et al. Clin Epigenetics. 2015;7(1):55.
  6. Rubio K, et al. Antioxidants. 2023;12(3):771.
  7. Rönn T, et al. PLoS Genet. 2013;9(6):e1003572.
  8. Bekdash RA. Nutrients. 2021;13(9):3111.
  9. Randunu RS, Bertolo RF. Int J Mol Sci. 2020;21(9):3290.
  10. Kadam I, et al. Clin Epigenetics. 2023;15(1):137.
  11. Łoboś P, Regulska-Ilow B. Rocz Państw Zakładu Hig. 2021.
  12. Sawicki C, et al. Proc Nutr Soc. 2023;82(3):359–369.
  13. DeLucas M, et al. Nutrients. 2024;16(6):770.
  14. Wu J, et al. Obes Rev. 2020;21(1):e12942.
  15. Niculescu MD, Zeisel SH. J Nutr. 2002;132(8):2333S–2335S.
  16. Rajendran P, et al. Int J Mol Sci. 2022;23(19):11712.
  17. Roy S, et al. Epigenetics. 2025;20(1):2491316.
  18. Casari G, et al. Biomolecules. 2024;15(1):15.
  19. Tozzi R, et al. Nutrients. 2022;14(15):3145.
  20. Elkin ER, et al. Curr Environ Health Rep. 2022;9(4):673–696.
  21. Noronha NY, et al. Environ Epigenetics. 2025;11(1):dvaf019.
  22. Kurita H, et al. Toxics. 2025;13(3):167.
  23. Liang Y, et al. Reprod Biol Endocrinol. 2025;23(1):80.
  24. Manikkam M, et al. PLoS ONE. 2013;8(1):e55387.
  25. Zhu L, et al. Toxins. 2017;9(4):113.
  26. Li L, et al. Environ Toxicol Pharmacol. 2023;100:104154.
  27. Sun Q, et al. Genes Environ. 2021;43(1):47.
  28. Krittanawong C, et al. Int J Cardiol Cardiovasc Risk Prev. 2023;19:200217.
  29. Stein RA, Riber L. microLife. 2023;4:uqad032.
  30. Villa C, Combi R. Int J Mol Sci. 2024;25(11):5970.
  31. Yan Y, et al. Nat Commun. 2024;15(1):873.
  32. Mani S, et al. Pediatr Res. 2025;97(4):1399–1410.

Publication Details

  • Article ID: O0701032   RA  Preprint
  • Received: 03/12/2025
  • Accepted: 28/12/2025
  • Published: 30/12/2025
  • DOI: Pending

Citations

Kudalkar S, Ranjan S, Arya S, Pradhan M. (2025). A Comprehensive Review of Environmental and Nutritional Influences on Epigenetic Change. Journal of Allbiosolution, 7(1).

Kudalkar S et al. A Comprehensive Review of Environmental and Nutritional Influences on Epigenetic Change. Journal of Allbiosolution, 2025.

Identification of Teriparatide by Sodium dodecyl sulfate polyacrylamide (SDS-PAGE)

Kashish Chaudhary2, Priyanka Chaudhary1, Anu Prakash1, Anubhuti Goyal1, Muthusamy Kalaivani1*, Meenakshi Dahiya1, Vivekanandan Kalaiselvan1

1 Biologics Division, Indian Pharmacopoeia Commission, Sector-23, Raj Nagar, Ghaziabad (U.P), India.

2 Amity Institute of Biotechnology, Amity University, Sector-125, Gautam Budh Nagar (U.P), India.

Corresponding Author

Dr. Muthusamy Kalaivani
Principal Scientific Officer,
Indian Pharmacopoeia Commission,
Ministry of Health and Family Welfare, Govt. of India,
Sector-23, Raj Nagar, Ghaziabad-201002, India.

Running Title

Identification of Teriparatide by SDS-PAGE

Abstract

Background: SDS-PAGE is a widely used technique for identifying and characterizing proteins based on their size and charge. Teriparatide, a synthetic form of the N-terminal fragment of human parathyroid hormone (PTH), can be identified through SDS-PAGE by its distinct molecular weight (~4.2 kDa) and migration pattern. This method enables the verification of its purity and confirmation of its protein structure during quality control processes.

Aim: The aim of this study is to identify teriparatide through SDS-PAGE by evaluating its molecular weight and migration characteristics in comparison to a reference standard. This technique allows for the accurate determination of its purity and helps confirm the integrity of the recombinant protein. Additionally, it provides a reliable method for distinguishing teriparatide from other protein contaminants. Ultimately, this approach supports quality control and ensures the consistency of the therapeutic agent.

Material & Method: In this study, we evaluated teriparatide via SDS-PAGE, checking its molecular weight for similarity and conducting qualitative analysis in comparison to a reference standard.

Results: Teriparatide's molecular weight and purity were evaluated using SDS-PAGE. Teriparatide (~4.2 kDa) is represented by a single band on polyacrylamide gel that was stained with silver nitrate. No additional bands were observed, suggesting minimal degradation or the presence of impurities. These results confirm the identity and purity of the teriparatide sample.

Conclusion: SDS-PAGE successfully identified teriparatide by revealing its distinct molecular weight and migration pattern. The technique confirmed the protein's purity, ensuring that it met the required standards for therapeutic use. The results also validated the structural integrity of the recombinant protein, distinguishing it from potential contaminants. SDS-PAGE proved to be an effective and reliable method for quality control in the production of teriparatide. Overall, this approach guarantees the consistency and safety of the therapeutic agent for clinical application.

Keywords

Teriparatide, SDS-PAGE, human parathyroid hormone, electrophoresis

References

  1. Falaschi, P., Marques, A., & Giordano, S. (2021). Osteoporosis and fragility in elderly patients. Orthogeriatrics: The management of older patients with fragility fractures, 35-52.
  2. Kothiyal, P., & Sharma, M. (2017). Post menopausal quality of life and associated factors—a review. American Journal of Pharm Research, 3(9), 7175-7183.
  3. Qaseem, A., Hicks, L. A., Etxeandia-Ikobaltzeta, I., Shamliyan, T., Cooney, T. G., Clinical Guidelines Committee of the American College of Physicians, & Tufte, J. E. (2023). Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Annals of internal medicine, 176(2), 224-238.
  4. Russell, G. (2024). Introduction: bone metabolism and its regulation. In Bone Markers (pp. 1-26). CRC Press.
  5. Jha, S. S. (2023). Biologics: Teriparatide and Newer Anabolics. Indian Journal of Orthopaedics, 57(Suppl 1), 135-146.
  6. Chilakapati, R., Mannully, C. T., & Pulicherla, K. K. (2019). Prospects of parathyroid hormone in therapeutic intervention. International Journal of Peptide Research and Therapeutics, 25, 961-977.
  7. Guerreiro, P. M., Renfro, J. L., Power, D. M., & Canario, A. V. (2007). The parathyroid hormone family of peptides: structure, tissue distribution, regulation, and potential functional roles in calcium and phosphate balance in fish. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 292(2), R679-R696.
  8. Osagie-Clouard, L., Sanghani, A., Coathup, M., Briggs, T., Bostrom, M., & Blunn, G. (2017). Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation. Bone & joint research, 6(1), 14-21.
  9. Raterman, H. G., Bultink, I. E., & Lems, W. F. (2019). Current treatments and new developments in the management of glucocorticoid-induced osteoporosis. Drugs, 79(10), 1065-1087.
  10. Dore, R. K. (2013). Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis. Patient preference and adherence, 435-446.
  11. Watanabe, A., Yoneyama, S., Nakajima, M., Sato, N., Takao-Kawabata, R., Isogai, Y., Sakurai-Tanikawa, A., et al. (2012). Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)). The Journal of toxicological sciences, 37(3), 617-629.
  12. Tashjian Jr, A. H., & Gagel, R. F. (2006). Teriparatide [human PTH (1‐34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. Journal of bone and mineral research, 21(3), 354-365.
  13. Cosman, F., Nieves, J. W., & Dempster, D. W. (2017). Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. Journal of bone and mineral research, 32(2), 198-202.
  14. Chandran, M., Akesson, K. E., Javaid, M. K., Harvey, N., Blank, R. D., Brandi, M. L., & Silverman, S. (2024). Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review. Osteoporosis International, 35(8), 1337-1358.
  15. Yoon, B. H., & Kim, K. C. (2020). Does teriparatide improve fracture union?: a systematic review. Journal of bone metabolism, 27(3), 167.
  16. Kovács, P., Schäfer, T., Háda, V., Hevér, H., Klingelhöfer, S., Nebel, M., & Urbányi, Z. (2020). Comparative physicochemical and biological characterisation of the similar biological medicinal product teriparatide and its reference medicinal product. BioDrugs, 34, 65-75.
  17. Chunxiao, W., Jingjing, L., Yire, X., Min, D., Zhaohui, W., Gaofu, Q., Xiangchun, S., Xuejun, W., Jie, W., Taiming, L. (2007). Study on preparation and activity of a novel recombinant human parathyroid hormone(1-34) analog with N-terminal Pro-Pro extension. Regul Pept, 141(1-3), 35-43.
  18. Fernández-Carneado, J., Vallès-Miret, M., Arrastia-Casado, S., Almazán-Moga, A., Macias, M.J., Martin-Malpartida, P., Vilaseca, M., Díaz-Lobo, M., Vazquez, M., Sanahuja, R.M., et al. (2024). First Generic Teriparatide: Structural and Biological Sameness to Its Reference Medicinal Product. Pharmaceutics, 16(4), 537.
  19. Ughade, S., Rana, S., Nadeem, M., Kumthekar, R., Mahajani, S., & Bhambure, R. (2024). Mechanistic Modeling of Size Exclusion Chromatography-Assisted In Vitro Refolding of the Recombinant Biosimilar Teriparatide (PTH-34). ACS Omega, 9(3), 3204-3216.
  20. Couchman, L., Taylor, D. R., Krastins, B., Lopez, M. F., & Moniz, C. F. (2014). LC-MS candidate reference methods for the harmonisation of parathyroid hormone (PTH) measurement: a review of recent developments and future considerations. Clinical Chemistry and Laboratory Medicine (CCLM), 52(9), 1251-1263.
  21. Sharma, N., Kukreja, D., Giri, T., Kumar, S., & Shah, R. P. (2022). Synthetic pharmaceutical peptides characterization by chromatography principles and method development. Journal of Separation Science, 45(13), 2200-2216.
  22. Wagner, W. J., Moyle, A. B., Wagner, N. D., Rempel, D. L., & Gross, M. L. (2024). Evaluating chemical footprinting-induced perturbation of protein higher order structure. Analytical chemistry, 96(23), 9693-9703.
  23. Patel, A., & Patel, R. (2023). Analytical method development for biologics: Overcoming stability, purity, and quantification challenges. Journal of Applied Optics, 44(1S), 1-29.
  24. Nowakowski, A. B., Wobig, W. J., & Petering, D. H. (2014). Native SDS-PAGE: high resolution electrophoretic separation of proteins with retention of native properties including bound metal ions. Metallomics, 6(5), 1068-78.
  25. Haider, S. R. (2012). Enhanced gel electrophoresis (GE) and inductively coupled plasma-mass spectrometry (ICP-MS) based methods for the identification and separation of proteins and pepides (Doctoral dissertation, Loughborough University).
  26. Mitsudome, T., Moribe, M., Obayashi, Y., Uchiyama, A., & Aono, M. (2020). Influence of low-molecular-weight aggregates on aggregate growth kinetics and physical properties of solid-state proteins during storage. Eur J Pharm Biopharm, 146, 10-18.
  27. Narayanan, H., Dingfelder, F., Morales, I. C., Patel, B., Heding, K. E., Bjelke, J. R., Egebjerg, T., Butté, A., Sokolov, M., Lorenzen, N., & Arosio, P. (2021). Molecular Pharmaceutics, 18, 3843-3853.

Publication Details

Citations

Chaudhary, K., Chaudhary, P., Prakash, A., Goyal, A., Kalaivani, M., Dahiya, M., & Kalaiselvan, V. (2025). Identification of Teriparatide by Sodium dodecyl sulfate polyacrylamide (SDS-PAGE). Journal of Allbiosolution, 7(1), 1–6.

Kashish Chaudhary et al. Identification of Teriparatide by Sodium dodecyl sulfate polyacrylamide (SDS-PAGE). Journal of Allbiosolution, 2025, 7(1): 1-6.

K. Chaudhary et al. Identification of Teriparatide by Sodium dodecyl sulfate polyacrylamide (SDS-PAGE). Allbiosolution, 2025, 7(1): 1-6.

Comparative Assessment of Filgrastim Bio-similars via vertical gel electrophoresis (SDS-PAGE) and HPLC

Priyanka Chaudhary 1, Muthusamy Kalaivani 1, Kashish Chaudhary 2, Anubhuti Goyal 1, Meenakshi Dahiya1, Rajeev Singh Raghuvanshi 1

1 Department of Biologics, Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Govt. India, Sector-23, Raj Nagar, Ghaziabad-201 002, India.

2 Department of Biotechnology, Bennett University, India

Abstract

Background: Filgrastim bio-similar have emerged as cost-effective alternatives to the reference filgrastim, providing comparable efficacy and safety profiles. Objective: In this study, we aim to show physico-chemical similarity between filgrastim biosimilars using vertical gel electrophoresis & high-performance liquid chromatography. Materials & Methods: In the present study, we evaluate filgrastim biosimilars (grafeel, religrast, neukine, colstim, emigrast) via SDS-PAGE and HPLC thereby checking their molecular weights for similarity and their qualitative analysis. The same was compared with reference standard of filgrastim (Filgrastim, certified Reference Material). Results: In the scope of the data obtained, we found that the main band of filgrastim in filgrastim biosimilars has the same electrophoretic mobility as the reference standard under non-reduced circumstances in case of SDS-PAGE, the outcomes demonstrated that the position of the principal band in the electropherogram produced by the test solution and the principal band produced by the reference solution are similar. The retention time of the main peak obtained with the test solution and the peak obtained with the reference solution are similar. For HPLC, all the filgrastim biosimilars showed monomer peaks on the RP-HPLC chromatograms, which eluted at 12.4 minutes, matching the retention duration of the filgrastim reference standard. Conclusion: Filgrastim has transformed the management of neutropenia and has become an indispensable therapy in various clinical settings. The development and approval of filgrastim biosimilars have expanded treatment options and improved accessibility, offered cost-effective alternatives while maintained comparable safety and efficacy. .  

Keywords: Filgrastim, Bio-similar, Physicochemical, SDS-PAGE, HPLC.

References:

1.    Sekhon B S: Biopharmaceuticals: An overview, Thai J. pharm Sci. 2010; 34:1-19
2.    Subbiah, V. The next generation of evidence-based medicine. Nat Med 29, 2023; 49-58. 
3.    Kirchhoff CF, Wang XM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: Key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696-705.
4.    Kim H, Alten R, Avedano L et al The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs. 2020; 80:99-113
5.    Halim L A, Marquez M, Maas-Bakker R F et al, Quality comparison of biosimilar and copy filgrastim products with the innovator product; Pharm Res 2018;35:226
6.    Hoglund M. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)–what is the difference? Med Oncol. 1998;15(4):229–33
7.    Herman AC, Boone TC, Lu HS. Characterization, formulation, and stability of Neupogen (Filgrastim), a recombinant human granulocyte-colony stimulating factor. Pharma Biotech. 1996;9: 303–28
8.    Hollingshead LM, Goa KL. Recombinant Granulocyte Colony-Stimulating Factor (rG-CSF). 1991; Drugs 42, 300–30 
9.    Panopoulos AD, Watowich SS. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine. 2008; 42(3):277-8
10.    Segal AW. How neutrophils kill microbes. Annu Rev Immunol. 2005; 23:197-223
11.    Lyman GH, Kuderer NM. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs. 2002;62 Suppl 1:65-78.
12.    Bendall L J, Bradstock K F, G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent, Cytokine & Growth Factor Reviews, 2014; 4: 25. 
13.    Awad M, Singh P, Hilas O. Zarxio (Filgrastim-sndz): The First Biosimilar Approved by the FDA. P T. 2017;42(1):19-23.
14.    Kraj L, Krawczyk-Lipiec J, Gorniewska J et al. Efficacy and safety of biosimilar filgrastim in primary and secondary prevention of febrile neutropenia. Biomed Rep. 2017; 2:143-47.
15.    Meher BR, Balan S, Mohanty RR, Jena M, Das S. Biosimilars in India; Current Status and Future Perspectives. J Pharm Bioallied Sci. 2019;11(1):12-15
16.    Joshi D, Khursheed R, Gupta S et al Biosimilars in Oncology: Latest Trends and Regulatory Status. Pharmaceutics. 2022;14(12):2721
17.    Sörgel, Fritz L, Lauber HT. Physicochemical and Biologic Comparability of a Biosimilar Granulocyte Colony-Stimulating Factor with Its Reference Product. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy.  2010;24: 347-57.
18.    Qureshi H, Veeresham C. and Srinivas C. Analytical Method Development and Validation of Filgrastim by UV and RP-UPLC Methods. American Journal of Analytical Chemistry 2021;12: 333-46.
19.    Hannah R, Eyers, Claire- Analysis of Post-translational Modifications by LC-MS/MS. Methods in molecular biology (Clifton, N.J.). 2010;658: 93-108.
20.    Jadaun GPS, Dixit S, Saklani V et al HPLC for Peptides and Proteins: Principles, Methods and Applications Pharm Methods. 2017; 8(1): 1-6
21.    Kirley TL, Norman AB. Unfolding of IgG domains detected by non-reducing SDS-PAGE. Biochem Biophys Res Commun. 2018;503(2):944-49.
22.    Mantovani M, Caruso C S, Antonio D F et al, Pharmacokinetic and pharmacodynamic properties of a new biosimilar filgrastim TPI G-CSF in comparison to the marketed reference filgrastim Neupogen: a double blind, single dose, two period cross over trial Dove press 2017;166:90.
23.    Macedo M K, Romero-Diaz A J, Miranda Hernandez M P, Duran K M, Flores-ortiz L F, Rivero E M; Characterization and comparability of biosimilars: a filgrastim case of study and regulatory perspectives for Latin America; Electronic J Biotech. 2016; 19:63-69. 
24.    Skrlin A, Radic I, Vuletic M et al Comparison of physicochemical properties of filgrastim; Science Direct 2010; 5:557-66. 
25.    Cory.E. Muraco; a fast and reliable method for purity analysis of filgrastim; reporter US 34.2. 
26.    Rathore AS, Bhambure R. Establishing analytical comparability for “biosimilars”: filgrastim as a case study. Anal Bioanal Chem. 2014; 406: 6569–76.  
27.    Tekdemir B, Seckin Z, Kacar AI et al. Evaluation of Structural, Biological, and Functional Similarity of Biosimilar Granulocyte Colony Stimulating Factor to its Reference Product. Pharm Res; 2020: 37:215
28.    Skrlin A, Radic I, Schwinke, D et al. Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals: Journal of the International Association of Biological Standardization. 2010; 38:557-66.
29.    Sörgel F, Schwebig A, Holzmann J, Prasch S, Singh P, Kinzig M. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. Bio Drugs. 2015; 29:123-31.

Publication
Article ID: O0601027 RA Preprint 
Received: 05/06/2024
Accepted: 19/06/2024
Published: 05/07/2024

DOI: 10.64307/allbiosolutionO0601027

Citations
P. Chaudhary et al. Comparative Assessment of Filgrastim Bio-similars via vertical gel electrophoresis (SDS-PAGE) and HPLC. Journal of Allbiosolution, 2024, 6(1):271-277
P. Chaudhary et al. Comparative Assessment of Filgrastim Bio-similars via vertical gel electrophoresis (SDS-PAGE) and HPLC. Allbiosolution, 2024, 6(1):271-277
 
How many times this paper is cited?

Study Of Physico-Chemical Parameters And Assessment Of Groundwater Quality Near Tamsa River In Azamgarh District (U.P)

Prem Yadav 1 and Rajesh Kumar Yadav 2

1 Department of Chemistry, N.S.P.S. Government P.G. College, Magaraha Mirzapur (U.P.) India 

2 Department Of Chemistry, Rajkiya Mahila Mahavidyalaya, Samdi, Azamgarh (U.P.) India

Abstract

Earth's surface contains different types of ores, salts and minerals which are dissolved by the water to increase salinity of groundwater. By the river, rain and other sources of water, the salts present on the surface meet in the groundwater and change their concentration. Salinity is caused as a result of dissolution of minerals like halite, anhydrite, carbonates, gypsum, fluoride-salts and sulphate salts. The physicochemical analysis of sample number S-1 to S-10 is colorless, odorless and without turbidity in summer and rainy season except sample S-3. This indicates that salt concentration in groundwater is low but sample S-3 in turbid and colour change on exposure in air after some time indicate that salt concentration and dissolved salt or metal ion concentration is high in area Gopalganj, Azamgarh. The PH= 6.96, TDS= 1200 ppt, electrical conductivity is 2260 Ms-1 indicate that water in this area is moderately hard and dissolution of minerals during water percolation in the rainy season becomes high. 

Keywords: Contamination, Electrical Conductivity, Ground Water, Hard water, Total Dissolve Salt 

References:

1. Ground water brochure of Azamgarh district A.A.P by Singh U.B. (2013), Asst. Hydro geologist of Azamgarh. 

2. Yadav Shailendra and Alauddin Shafqat(2017) International Journal of Emerging Technologies in Engineering Research (IJETER)24-26, Volume 5, Issue 10, October. 

3. U.P. Jal nigam wesite www.upjn.org 

4. Jha A.N. and Verma P.K.(2000) Physico-chemical property of drinking water in town area of Godda district under Santhal Pragana, Bihar, Poll. Res. 19(20), 245-247. 

5. APHA(American public health association)(1980) American water works association and water pollution control federation Standard method for the examination of water and waste water. 

6. BIS( Bureau of Indian standard) Indian standard specification for drinking water (1992) 

7. Dilek A. Atasoy and Irfan Yesilnacar M., (2011), Chapter 8 in book title “Water Recycling and Water Management” editor: Daniel M. Carrey, page 1-20. 

8. ICMR (Indian council of medical research), manual of standard of quality (1975). 

9. Chemical Biological Methods for Water Pollution Studies author:.Trivedi R.K and Goel P.K (1984). 

10. Raghunath H.M. (2007) , Groundwater, 3rd Edition, New Age International (P) Ltd., Publishers, New Delhi, 1-308. 

11. Sunderay S.K., Panda U.C, Nayak B.B. and Bhatia (2006), Multivariate statistical technique for the evaluation of spatial and temporal variation in water quality of Mahanadi river-estuarine system in India a case study environmental geo- chemistry and health. 

12. Central water ground board (Report) (2010). 

13. Draft, national water policy (2010), Central water commission, New Delhi. 

14. Asthana Nirbhaya and Dwivedi Anil Kumar, (2021) IJCRT, 9, Issue 5,124-131. 

15. Saxena Umesh and Saxena Swati,(2015), Int. J. of Environment Science and Technology,vol. 1,Issue 1,78-91. 

16. Vijaykumar H., Patil Nagraj S.,Prabhu Nanjundi (2020), AIP Conf. Proc., 2204(1):020025. 

17. Siebert s., Burke J., Faures J. M., Frenken K., Hoogeveen J., Döll P., and Portmann F. T. (2010), HESS, volume 14, 1863-1880 

18. Guideline for drinking water quality fourth edition W.H.O. (2011). 

19. Srivastava Sheila and Kumar Shiv,(2011) Indian Journal of Environmental Health, 53(1)85-8. 

20. Anwar Khwaja Mohammad and Aggarwal Dr.Vanita (2017) World Journal of Engineering Research and Technology, Vol. 3, Issue 6, 380-388. 

21. Parveen Mathur and Pooja Tomar(2011), Int- J. Chem Science 9 (3) 1319-1333.

Publication
Article ID: O0401018   RA  Preprint
Received: 30/04/2022 
Accepted: 30/06/2022
Published: 30/10/2022

Association of anti-diabetic medications with DILI: A Disproportionality analysis

Javed Faiza and Kumar Anoop

Department of Pharmacology and Clinical Research, Delhi Pharmaceutical Sciences and Research University Pushp Vihar, Sec-III, MB Road, New Delhi, INDIA

Abstract

Various classes of drugs are being used in the management of diabetes mellitus. These drugs are associated with various ADRs;however, association of anti-diabetic medications are not known for drug induced liver injury (DILI). Thus, we have tried to identify an association of anti-diabetic medications with DILI. The individual case safety reports (ICSRs) were extracted from FAERS data base from January 1, 2004, (2004Q1) to December 31, 2021 (2021Q3). The reporting odds ratio (ROR), Proportional Reporting Ratios (PRRs) with associated Chi-square value was calculated with 95% confidence interval. The majority of anti-diabetic drug induced liver injury cases were found in the 18–64 years and ≥ 65 years age groups. The number of cases in male and females were almost similar. The disproportionality analysis (PRR, ROR, reports count) results have shown a significant association of drug induced liver injury with antidiabetic medications. A total of 9120 cases of drug induced liver injury were reported out of which 726 are associated with antidiabetic drugs. The subgroup analysis results have also shown significant association. The sensitivity analysis has shown decrease in the strength of signal however, association was found positive. In conclusion, we have identified a novel signal of DILI associated with antidiabetic medications.   

Publication
Article ID: O0401019 (Suppl 1)   RA  Preprint
Received: 08/06/2022 
Accepted: 08/07/2022
Published: 08/08/2022

Pharmacovigilance Study Among Covid-19 Subjects And Subjects Vaccinated Against Covid-19 At National Heart Institute

Chand Neha, Mathur Rajani, Dwivedi Shridhar

Delhi Pharmaceutical Sciences and Research University Pushp Vihar, Sec-III, MB Road, New Delhi, INDIA

Abstract

Corona Virus Induced Disease (COVID-19) has emerged as a dreaded pandemic which is a threat to the entire world. It all began in Wuhan, China in December 2019 and rapidly spread over the world. It is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is an enveloped virus single-stranded, positive-sensed ribonucleic acid (RNA) virus that enters the host cell lungs via endocytosis or membrane fusion utilizing the ACE-2 receptor. The virus particles release and replicates into new progenies, which causes cytokine storm in some cases by releasing pro-inflammatory mediators into the lungs. It dominantly manifests as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and eventually involves all systems of human body. The pandemic is still going on though intermittently in various parts of the world. As on 15th July 2021, approximately 189 million COVID-19 infected cases have been reported worldwide, with over 4 million individuals dying as a result. In India, so far there are approximately 31 million infected cases and 4 lakhs human lives have been lost. Various antivirals, antibiotics, corticosteroids and other adjuvant therapies were being experimentally employed for COVID-19 prophylaxis and treatment. Many pharmaceutical companies have worked on COVID-19 vaccinations to stop the virus progression and transmission. In several countries, including India, the United States and Russia, the COVID-19 vaccine has already been approved for human use. India has been able to produce two vaccines namely Covaxin and Covishield and launch a massive vaccination drive for people above 18 years adults. Till now approximately, 304 million subjects have been partially vaccinated and 73 million subjects are fully vaccinated .Various other COVID-19 vaccines are in phase 3 of clinical development. Vaccines against covid is a major tool against progression and prevention of covid-19. Key words: Covid-19, Vaccines, Covishield and Covaxin.   

Publication
Article ID: O0401019 (Suppl 1)   RA  Preprint
Received: 08/06/2022 
Accepted: 08/07/2022
Published: 08/08/2022

Systematic review of failure of primary total hip arthroplasty and meta-analysis of safety profile of two different material of acetabular cup

Sharma A, Sural S, Kumar AA, Kalaiselvan V,Mathur R

Delhi Pharmaceutical Sciences and Research University Pushp Vihar, Sec-III, MB Road, New Delhi, INDIA

Abstract

Modern Total Hip Arthroplasty (THA) has advanced in technique and materials yet the occasional complications continue to haunt the surgeons. Aseptic loosening, osteolysis, wear, metallosis and implant breakage, are major concerns of materiovigilance of medical devices to develop safer materials for implants. To systematically analyze and review the adverse events (AE) after THA and a Meta analysis to associate the risk of implant failure with cross linked and vitamin E diffused polyethylene liner of THA. PubMed data bases showing observational studies and randomized clinical trials from 2016- 2020. The outcome of interest was defined as“ adverse events or complications” after THA and the factors responsible for the complications. Among the 48 eligible studies included in this review, the commonest implant was metal-on-polyethylene (MoP), whereas metal-on-metal (MoM) had the highest complications. Out of the total number of subjects1.83% had experienced an AE. Meta-analysis plot probably favours the safety of vitamin E diffused polyethylene liner material compared to cross linked polyethylne. The systematic review analysis suggests that the failure rate of THA is very low. More failures are observed in uncemented fixation type and MoM bearing hip implants. From the meta-analysis it can be concluded that the vitamin E diffused polyethylene liner is better in terms of safety than the conventional cross-linked polyethylene liner.   

Publication
Article ID: O0401019 (Suppl 1)   RA  Preprint
Received: 08/06/2022 
Accepted: 08/07/2022

Published: 08/08/2022